The long arm of BRAF V600E gets to mTORC1

Abstract

Despite the disappointing results of early clinical studies, targeting the BRAF ⁄ MEK⁄ extracellular signal-regulated kinase (ERK), mitogen-activated protein kinase (MAPK) pathway is still a subject of investigation due to its biological relevance to melanoma. It is now evident that to antagonize redundant protein functions and compensatory signaling pathways BRAF inhibitors must be combined with inhibitors of other relevant pathways based on a strong rational basis. Thus, we must expand our understanding of MAPK effectors and how MAPK interacts with those other pathways.